Azacitidine

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Azacitidine
   1. Pharmacist Assessment Report
   2. Azacitidine
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Cytotoxicity
   8. Safety Considerations
   9. Disclaimer

---

Pharmacist Assessment Report

Azacitidine

Summary

The TxGNN deep-learning model produced no candidate with a score of 0.99 or higher for Azacitidine, so there is currently no new predicted indication. The uses recorded for this drug are listed below.

Quick overview

Item	Content
Known uses recorded for this drug	15
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
leukemia, myeloid, acute	licence in another country
leukemia, myelomonocytic, chronic	licence in another country
myelodysplastic syndromes	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
acute myeloblastic leukemia with maturation
acute myeloblastic leukemia without maturation
acute myeloid leukemia with cebpa somatic mutations
acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2)
acute myeloid leukemia with minimal differentiation
acute myeloid leukemia with npm1 somatic mutations
acute myeloid leukemia with t(6;9)(p23;q34)
acute myeloid leukemia with t(8;16)(p11;p13) translocation
acute myeloid leukemia with t(8;21)(q22;q22) translocation
acute myeloid leukemia with t(9;11)(p22;q23)
inherited acute myeloid leukemia
myelodysplastic syndrome

Australia Market Information

Licence	Product	Dosage form	Status
12771E	Azacitidine Accord	Powder for injection 100 mg	Valid

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (hypomethylating nucleoside analogue)
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	FBC with differential, liver and renal function
Handling Protection	Follow cytotoxic drug handling regulations

---

Safety Considerations

• Contraindications flagged in the knowledge graph (not label text): liver failure, kidney disease, pyoureter, thrombocytopenia, neutropenia and agranulocytosis.
• Drug Interactions: 85 interactions were identified. Major-level examples include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib and live BCG vaccine. Moderate-level examples include zidovudine, ganciclovir, azathioprine, chloramphenicol, alemtuzumab and roflumilast.

Label-based warnings and contraindications were not available. Please refer to the TGA-approved Product Information (PI) for full safety information.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---